Femminella, Grazia Daniela <br/><br/>
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).  [electronic resource] 

 -  Trials  04 2019 
 - 191 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1745-6215 
<br/><br/><label>Standard No.: </label>10.1186/s13063-019-3259-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Activities of Daily Living<br/>Alzheimer Disease--drug therapy<br/>Brain--drug effects<br/>Clinical Trials, Phase II as Topic<br/>Cognition--drug effects<br/>Double-Blind Method<br/>Glucagon-Like Peptide-1 Receptor--metabolism<br/>Glucose--metabolism<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Liraglutide--adverse effects<br/>Memory--drug effects<br/>Multicenter Studies as Topic<br/>Neuroprotective Agents--adverse effects<br/>Randomized Controlled Trials as Topic<br/>Severity of Illness Index<br/>Time Factors<br/>Treatment Outcome<br/>United Kingdom<br/>Glucagon-Like Peptide-1 Receptor Agonists